Showing results (61-70 of 118) with videos related to
Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2022
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung CancerRoy S Herbst, Margarita Majem, Fabrice Barlesi, et al.Journal of Geriatric Oncology|February 21, 2015
Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301)Gaetan Des Guetz, Thierry Landre, Virginie Westeel, et al.BMC Cancer|December 17, 2014
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III studyIsabelle Borget, Maurice Pérol, David Pérol, et al.JAMA Network Open|July 15, 2025
Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical TrialCharu Aggarwal, Alex Martinez-Marti, Margarita Majem, et al.Translational Oncology|September 6, 2025
MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trialGuénaëlle Levallet, Christian Creveuil, Alexandre Léger-Vigot, et al.International Journal of Cancer|March 9, 2022
A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trialElodie Maille, Jérôme Levallet, Fatéméh Dubois, et al.European Journal of Cancer (Oxford, England : 1990)|June 3, 2026
Real-life management and outcomes of octogenarians with non-small-cell lung cancer: A 10-year evolutionRomain Corre, Isabelle Monnet, Lionel Moreau, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 18, 2013
Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III studyOlivier Bylicki, Céline Ferlay, Christos Chouaid, et al.Pathology|June 4, 2024
Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practiceSimon Garinet, Audrey Lupo, Thomas Denize, et al.Lung Cancer (Amsterdam, Netherlands)|September 13, 2014
Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01)Christos Chouaid, Cecile Dujon, Pascal Do, et al.Pageof 12